Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities (2016 - 2025)

Adma Biologics' Cash from Financing Activities history spans 13 years, with the latest figure at -$9.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 70.61% year-over-year to -$9.1 million; the TTM value through Dec 2025 reached -$44.0 million, up 24.49%, while the annual FY2025 figure was -$44.0 million, 24.49% up from the prior year.
  • Cash from Financing Activities reached -$9.1 million in Q4 2025 per ADMA's latest filing, up from -$27.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $62.7 million in Q4 2022 to a low of -$39.0 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $4.4 million, with a median of -$340520.5 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: surged 1014330.22% in 2021, then crashed 6221.88% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $53.8 million in 2021, then rose by 16.58% to $62.7 million in 2022, then tumbled by 162.15% to -$39.0 million in 2023, then increased by 20.44% to -$31.0 million in 2024, then surged by 70.61% to -$9.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Cash from Financing Activities are -$9.1 million (Q4 2025), -$27.8 million (Q3 2025), and $48000.0 (Q2 2025).